



**PARTICIPANT STATISTICS**

**FIRST QUADRIMESTER 2011**

**CHLAMYDIA / GC / STREP GROUP B ANTIGEN**

**Chlamydia**

Method	Specimen 1		Specimen 2		Pos Refer for ID	Specimen 3		Specimen 4		Specimen 5		No. of Labs
	Neg	Pos	Neg	Pos		Neg	Pos	Neg	Pos	Pos	Pos Refer for ID	
BD ProbeTec ET/Viper	32			32		30	2	30	2	32		32
Gen-Probe APTIMA Combo 2	21			21		21		20	1	21		21
Gen-Probe Pace 2	9			9		9		9		9		9
Inverness Clearview	14			14		14		14		14		14
Quidel QuickVue	13			12	1	13		13		12	1	13
Roche Amplicor	8			7		8		8		7		8
<b>Total Population</b>	<b>103</b>	<b>0</b>	<b>0</b>	<b>101</b>	<b>1</b>	<b>101</b>	<b>2</b>	<b>99</b>	<b>4</b>	<b>101</b>	<b>1</b>	<b>103</b>
<b>Flagging</b>		*****	*****				*****		*****			

**Neisseria gonorrhoeae**

Method	Specimen 1		Specimen 2		Specimen 3		Pos Refer for ID	Specimen 4		Specimen 5		No. of Labs
	Neg	Pos	Neg	Pos	Neg	Pos		Pos	Neg	Pos		
BD ProbeTec ET/Viper	31	1	32		32			32		31	1	31
Gen-Probe APTIMA Combo 2	21		21		21			21		21		21
Gen-Probe Pace 2	8		8		8			7	1	8		8
Roche Amplicor	8		8		8			8		8		8
<b>Total Population</b>	<b>72</b>	<b>1</b>	<b>73</b>	<b>0</b>	<b>73</b>	<b>0</b>	<b>1</b>	<b>72</b>	<b>1</b>	<b>72</b>	<b>1</b>	<b>73</b>
<b>Flagging</b>		*****		*****		*****					*****	

**Strep Group B**

Method	Specimen 1		Specimen 2		Specimen 3		Specimen 4		Specimen 5		No. of Labs
	Neg	Pos	Neg	Pos	Neg	Pos	Neg	Pos	Neg	Pos	
Remel Wellcogen		1	1			1	1			1	1
BD Directigen-latex		3	3			3	3			3	3
Gen-Probe AccuProbe		2	2			2	2			2	2
Remel PathoDX		2	2			2	2			2	2
<b>Total Population</b>	<b>0</b>	<b>8</b>	<b>8</b>	<b>0</b>	<b>0</b>	<b>8</b>	<b>8</b>	<b>0</b>	<b>0</b>	<b>8</b>	<b>8</b>
<b>Flagging</b>	*****			*****	*****			*****		*****	

Correct responses are defined as those reflecting agreement among 80% or more of all participants or referees. Unacceptable responses are indicated by "\*\*\*\*\*" on the Flagging line of each specimen.